Breaking Finance News

A statement released earlier today by Gabelli about K2M Group (NASDAQ:KTWO) ups the target price to $22.00

Displaying a price of $17.17, K2M Group (NASDAQ:KTWO) traded 0.76% higher on the day. The last stock close is up 15.92% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time period. The company has recorded a 50-day moving average of $16.57 and two hundred day average of $14.92. Volume of trade was was down over the average, with 58,334 shares of KTWO changing hands under the typical 321,112 shares.

In a report released on 9/16/2016 Gabelli bumped up the target price of K2M Group (NASDAQ:KTWO) from $0 to $22 indicating a possible upsideof 0.28%.

Recent Performance Graph:


A total of 7 brokers have released a report on KTWO. Zero rate the company a strong buy, 0 rate the company a buy, 0 firms rate the company a hold, 0 rate the stock to underperform, and finally 0 analystsrate the stock as sell with a consensus target stock price of $20.43

K2M Group has a one-year low of $10.10 and a one-year high of $23.00 and has a total market value of $0.0.

Brief Synopsis On K2M Group (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company’s technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, and CASCADIA and tifix.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *